Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs

ClinicalTrials.gov ID: NCT00002240

Public ClinicalTrials.gov record NCT00002240. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Evaluation of the Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, Alone and in Combination With d4T and ddI as Compared to a Reference Combination Regimen

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate a new protease inhibitor known as BMS-232632. This drug will be given in combination with 2 other anti-HIV drugs (stavudine and didanosine). The effectiveness of BMS-232632 against HIV infection will be compared to that of nelfinavir, a protease inhibitor that is already commonly prescribed.

Study identification

NCT ID: NCT00002240
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

HIV Infections

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 28, 1999
Primary completion: Nov 30, 2001
Completion: Nov 30, 2001
Last update posted: May 3, 2011

1999 – 2001

United States locations

U.S. sites: 16
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
Clinsites / Sorra Research Ctr	Birmingham	Alabama	35203	—
Univ of Alabama at Birmingham	Birmingham	Alabama	35294	—
UCSD Treatment Ctr	San Diego	California	92103	—
UCSF - San Francisco Gen Hosp	San Francisco	California	94110	—
Univ of Colorado / Health Science Ctr	Denver	Colorado	80262	—
ViRx / Dupont Circle Physicians Group	Washington D.C.	District of Columbia	20009	—
AIDS Research Consortium of Atlanta	Atlanta	Georgia	30308	—
Rush Presbyterian - Saint Luke's Med Ctr	Chicago	Illinois	60612	—
Washington Univ School of Medicine	St Louis	Missouri	63108	—
Albany Med College	Albany	New York	12208	—
Beth Israel Med Ctr	New York	New York	10003	—
Columbia Presbyterian Med Ctr	New York	New York	10032	—
Case Western Reserve Univ	Cleveland	Ohio	44106	—
Oak Lawn Physicians Group	Dallas	Texas	75219	—
Univ of Texas Southwestern Med Ctr of Dallas	Dallas	Texas	75235	—
Univ TX Galveston Med Branch	Galveston	Texas	77555	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00002240, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 3, 2011 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00002240 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →